Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for diabetic nerve pain? drug tested in 61 patients

NCT ID NCT03172598

Symptom relief Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called MT-8554 in 61 adults with painful diabetic peripheral neuropathy, a common complication of diabetes causing nerve pain. The goal was to see if the drug could safely reduce pain compared to a placebo. Participants took the drug or placebo in random order, and researchers measured pain levels and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

61 people

The number who actually took part.

Started

Jul 2017

Finished

Aug 2018

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male subjects and female subjects aged ≥18 years * Subjects who have a history of pain at least 6 months and ≤7 years attributed to diabetic peripheral neuropathy * A body mass index ranging from 18 to 45 kg/m2 Exclusion Criteria: * Subjects who have participated in a clinical study of any IMP (other than placebo) within 12 weeks (from last administration) prior to screening or who are currently participation in another clinical study * Unstable or uncontrolled diabetes * Clinically significant 12-lead ECG abnormalities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Painful diabetic peripheral neuropathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Painful diabetic peripheral neuropathy

Contacts and locations

Locations

  • Investigational center

    City Name, Germany

  • Investigational center

    City Name, Hungary

  • Investigational center

    City Name, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.